Clontech Laboratories, Inc. Releases the DNA SMART™ ChIP-Seq Kit

MOUNTAIN VIEW, Calif., Sept. 22, 2014 /PRNewswire/ -- Clontech Laboratories, Inc., a wholly-owned subsidiary of Takara Bio Inc., today announced the launch of the DNA SMART ChIP-Seq Kit. This kit adapts Clontech's patented SMART® technology in an innovative manner for use with low-input samples, including both dsDNA and ssDNA templates, to generate ChIP-seq libraries for NGS.

SMART (Switching Mechanism at 5' End of RNA Template) technology, when applied to RNA, allows for full-length cDNA synthesis with direct addition of a PCR adaptor. In the DNA SMART ChIP-Seq Kit, a novel, patent-pending adaptation of template switching technology is used to add Illumina®-specific adaptors directly to DNA. This produces ChIP-seq libraries without additional ligation or clean-up steps. The process has resulted in the simplification of library generation, cutting down protocol time significantly compared to traditional, ligation-based methods of adapter addition. The DNA SMART ChIP-Seq Kit generates libraries with good complexity and low redundancy from low-input samples (100 pg–10 ng) using a simple protocol that can be completed in half a day.

"Clontech is known as a leader in cDNA synthesis, and in recent years SMART technology has been widely acclaimed as the gold standard for sensitive transcriptome analysis from low-input samples, including single cells," said Carol Lou, General Manager of Clontech Laboratories, Inc. "With the DNA SMART ChIP-Seq Kit we are able to expand the benefits of SMART technology into other NGS applications. Our focus has been providing new solutions to customers, enabling them to work with challenging samples. This kit allows us to address the needs of those researchers working with low inputs of either dsDNA or ssDNA for NGS applications."

The launch of the DNA SMART ChIP-Seq Kit continues the Clontech® tradition of supporting good science by providing new tools to meet the ever-changing needs of life science researchers. For more information about Clontech products for NGS, please visit: www.clontech.com/NGS.

About Clontech Laboratories, Inc.

Clontech Laboratories, Inc., a wholly-owned subsidiary of Takara Bio Inc., develops, manufactures, and distributes a wide range of life science research reagents under the Clontech and Takara® brands. Key products include SMARTer® cDNA synthesis kits for a variety of samples and applications, including NGS; high-performance qPCR and PCR reagents (including the TaKaRa Ex Taq®, TaKaRa LA Taq®, Titanium®, and Advantage® enzymes); RT enzymes and SMART library construction kits; the innovative In-Fusion® cloning system; Tet-based inducible gene expression systems; Living Colors® fluorescent proteins; and a range of Macherey-Nagel nucleic acid purification tools. These and other products support applications including NGS, gene discovery, regulation, and function; protein expression and purification; RNAi and stem cell studies; and plant and food research. For more information, visit www.clontech.com.

 About Takara Bio Inc.

Takara Bio Inc. is an innovative biotechnology company based in Shiga, Japan. As a world leader in biotechnology research and development, Takara Bio was the first company to market PCR technology in Japan and is also the developer of the RetroNectin® reagent, which is used as a world standard in gene therapy protocols. In addition to providing research reagents and equipment to the life science research market, Takara Bio has active research and product development activities in the fields of gene and cell-based therapy and agricultural biotechnology; and is committed to preventing disease and improving the quality of life for all people through the use of biotechnology. Through strategic alliances with other industry leaders, Takara Bio aims to extend its reach around the world. More information is available at www.takara-bio.com.

Photo - http://photos.prnewswire.com/prnh/20140919/147374-INFO
Logo - http://photos.prnewswire.com/prnh/20131021/SF99259LOGO

SOURCE Clontech Laboratories, Inc.